Transcript Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer

National Patterns of Care Study in
Breast Cancer
• Launched October 2010
• 100 US-based community oncologists surveyed
• Proportion of patients/office visits with breast cancer:
30% (median)
• New patients with breast cancer seen per month:
15 (median)
Copyright © 2011, Research To Practice, All rights reserved.
What percentage of the time did the Oncotype DX®
results cause you to alter your preconceived
treatment recommendation?
25%
Median
0
Patterns of Care in Breast Cancer,
Research To Practice 2010.
10
20
30
40
Copyright © 2011, Research To Practice, All rights reserved.
60 yo woman: 1.0-cm sentinel node-negative
IDC. Which adjuvant chemotherapy treatment
would you recommend?
Tumor Subtype
ER+/HER2-neg, would order
Oncotype DX (n = 82)
High RS
Intermediate RS
Low RS
ER+/HER2-neg, would not
order Oncotype DX (n = 18)
Patterns of Care in Breast Cancer,
Research To Practice 2010.
Anthra 
Taxane
TC
AC
Other
None
30%
7%
0%
60%
62%
4%
6%
4%
0%
4%
1%
3%
0%
26%
93%
0%
6%
0%
6%
88%
Copyright © 2011, Research To Practice, All rights reserved.
75 yo woman: 1.0-cm sentinel node-negative
IDC. Which adjuvant chemotherapy treatment
would you recommend?
Tumor Subtype
ER+/HER2-neg, would order
Oncotype DX (n = 46)
High RS
Intermediate RS
Low RS
ER+/HER2-neg, would not
order Oncotype DX (n = 54)
Patterns of Care in Breast Cancer,
Research To Practice 2010.
Anthra 
Taxane
TC
AC
Other
None
22%
3%
0%
63%
37%
4%
11%
4%
0%
2%
4%
2%
2%
52%
94%
0%
11%
0%
4%
85%
Copyright © 2011, Research To Practice, All rights reserved.
60 yo woman: 3.4-cm sentinel node-negative
IDC. Which adjuvant chemotherapy treatment
would you recommend?
Tumor Subtype
ER+/HER2-neg, would order
Oncotype DX (n = 64)
High RS
Intermediate RS
Low RS
ER+/HER2-neg, would not
order Oncotype DX (n = 36)
Patterns of Care in Breast Cancer,
Research To Practice 2010.
Anthra 
Taxane
TC
AC
Other
None
38%
11%
3%
53%
72%
11%
6%
6%
2%
2%
2%
2%
2%
9%
82%
33%
42%
11%
6%
8%
Copyright © 2011, Research To Practice, All rights reserved.
75 yo woman: 3.4-cm sentinel node-negative
IDC. Which adjuvant chemotherapy treatment
would you recommend?
Tumor Subtype
ER+/HER2-neg, would order
Oncotype DX (n = 61)
High RS
Intermediate RS
Low RS
ER+/HER2-neg, would not
order Oncotype DX (n = 39)
Patterns of Care in Breast Cancer,
Research To Practice 2010.
Anthra 
Taxane
TC
AC
Other
None
16%
3%
2%
69%
46%
6%
5%
3%
2%
7%
5%
5%
3%
43%
85%
5%
41%
5%
13%
36%
Copyright © 2011, Research To Practice, All rights reserved.
60 yo woman: 1.0-cm IDC (2 positive nodes).
Which adjuvant chemotherapy treatment would
you recommend?
Tumor Subtype
ER+/HER2-neg, would order
Oncotype DX (n = 24)
High RS
Intermediate RS
Low RS
ER+/HER2-neg, would not
order Oncotype DX (n = 76)
Patterns of Care in Breast Cancer,
Research To Practice 2010.
Anthra 
Taxane
TC
AC
Other
None
38%
29%
8%
50%
58%
8%
4%
0%
4%
4%
0%
4%
4%
13%
76%
58%
24%
7%
6%
5%
Copyright © 2011, Research To Practice, All rights reserved.
75 yo woman: 1.0-cm IDC (2 positive nodes).
Which adjuvant chemotherapy treatment would
you recommend?
Tumor Subtype
ER+/HER2-neg, would order
Oncotype DX (n = 44)
High RS
Intermediate RS
Low RS
ER+/HER2-neg, would not
order Oncotype DX (n = 56)
Patterns of Care in Breast Cancer,
Research To Practice 2010.
Anthra 
Taxane
TC
AC
Other
None
25%
11%
0%
57%
50%
12%
5%
0%
2%
11%
9%
2%
2%
30%
84%
32%
34%
7%
9%
18%
Copyright © 2011, Research To Practice, All rights reserved.